Sponsored by the University of Kentucky College of Medicine
ACPE-accredited and produced by North American Center for Continuing Medical Education-Princeton CME
Statement of Need
Type 2 diabetes is a common, chronic, and expensive disease that affects nearly 20 million individuals in the United States. The increased prevalence of type 2 diabetes, which is largely attributed to the alarming increase in the US obesity rate, results in a substantial clinical burden, including an increased risk of cardiovascular death. Costs associated with diabetes and its related comorbidities total more than $170 billion annually. Morbidity and mortality in patients with type 2 diabetes is often linked to inadequate glycemic control. Recent studies have demonstrated that despite the availability of appropriate therapy and an increasing antidiabetic treatment armamentarium, glycemic control in patients with type 2 diabetes deteriorates over time and more than 60% of individuals with this condition are insufficiently managed. Hospital pharmacists and managed markets professionals may benefit from education on current and emerging evidence-based approaches to ensure proper glycemic management to optimize patient outcomes and ensure efficient healthcare resource use.
Target Audience
This activity is designed for hospital pharmacists and managed markets professionals.
Learning Objectives
After completing this activity, participants should be able to:
- Describe the prevalence and burden of type 2 diabetes, including frequent comorbidities, such as obesity and cardiovascular disease (CVD)
- Explain the importance of tight glucose control in type 2 diabetes management and its correlation with obesity and CVD
- Outline the benefits and limitations of current and emerging medications and combinations for type 2 diabetes management
- Implement evidence-based approaches to type 2 diabetes management to optimize patient outcomes across the continuum of care
Credit Eligibility
To be eligible for documentation of credit, participants must participate in the full educational activity, complete the 10-question post-test with a score of 70% or better, and complete the evaluation form. Participants who successfully complete the post-test and evaluation form online may immediately print their documentation of credit. Those who mail or fax back their successfully completed post-test and evaluation form will receive documentation of credit by mail within 6 weeks.
Participants who have successfully completed the live version of this activity are not eligible to receive credit for this enduring material.
Release date: September 5, 2008;
Expiration date: September 5, 2009
Estimated time to complete: 1 hour
There is no fee associated with this activity.
Lecture Components
The presentation slides, accredited articles in PDF format, post-test, and evaluation form are available as a click through via the menu at the top of each page of this educational activity.
CME Accreditation
The University of Kentucky College of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The University of Kentucky College of Medicine designates this educational activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
The University of Kentucky College of Medicine presents this activity for educational purposes only. Participants are expected to utilize their own expertise and judgment while engaged in the practice of medicine. The content of the presentations is provided solely by presenters who have been selected for presentations because of recognized expertise in their field.
The University of Kentucky is an Equal Opportunity University.
University of Kentucky College of Medicine test code: XEN08182, XEN08183
CPE Accreditation
Princeton CME is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education (ACPE Provider #452) and complies with the Criteria for Quality and Interpretive Guidelines. This activity is approved for 1 contact hour (0.1 CEU) of continuing pharmacy education (UPN 452-999-08-021-H01-P).
Any participant wanting to file a grievance with respect to any aspect of a continuing pharmacy education activity accredited by Princeton CME may contact John Savage, Director, Medical Education, North American Center for Continuing Medical Education (NACCME)-Princeton CME, in writing. The Director, Medical Education will review the grievance and respond within 30 days of receiving the written statement. If the participant is unsatisfied with the response, an appeal to the Vice President, Medical Education, NACCME-Princeton CME, may be made for a second level of review.
John Savage
NACCME-Princeton CME
300 Rike Drive, Suite A
Millstone Township, NJ 08535
E-mail: jsavage@naccme.com
Independent Clinical Reviewer: Derek LeRoith, MD, PhD, Chief, Division of Endocrinology, Diabetes, and Bone Diseases, Mount Sinai School of Medicine, New York, New York
Grant Support
Supported by an educational grant from Amylin Pharmaceuticals, Inc, and Eli Lilly and Company.
Participating Faculty
Andrew J. Ahmann, MD
Director, Harold Schnitzer Diabetes Health Center
Associate Professor, Oregon Health and Science University
Portland, Oregon
Jeremy Gleeson, MD
Endocrinologist
Associate Medical Director
ABQ Health Partners
Albuquerque, New Mexico
Stuart T. Haines, PharmD, FCCP, FASHP
Professor and Pharmacotherapy Specialist
University of Maryland School of Pharmacy
Joslin Diabetes Center at University of Maryland
Baltimore, Maryland
Curtis Triplitt, PharmD, CDE
Texas Diabetes Institute
Clinical Assistant Professor of Medicine, Division of Diabetes
University of Texas Health Science Center
San Antonio, Texas
Financial Disclosure and Conflicts of Interest
According to the disclosure policy of the University of Kentucky College of Medicine and NACCME-Princeton CME, faculty, editors, managers, and other individuals who are in a position to control content are required to disclose any relevant financial relationships with relevant commercial companies related to this activity. All relevant conflicts of interest that are identified are reviewed for potential conflicts of interest. If a conflict is identified, it is the responsibility of the University of Kentucky College of Medicine and NACCME-Princeton CME to initiate a mechanism to resolve the conflict(s). The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation.
All educational materials are reviewed for fair balance, scientific objectivity of studies reported, and levels of evidence.
The faculty has reported the following:
Dr. Ahmann: Speakers bureau—Amylin Pharmaceuticals, Inc, Eli Lilly and Company, Merck & Co, Inc, sanofi-aventis U.S.; Contract research support—Amylin Pharmaceuticals, Inc, Eli Lilly and Company, Medtronic; Consultant—Novo Nordisk
Dr. Gleeson: Speakers bureau—Amylin Pharmaceuticals, Inc, Diiachi Sankyo, Inc, Merck & Co, Inc, Novartis, Takeda Pharmaceuticals North America, Inc
Dr. Haines: Consultant—Amylin Pharmaceuticals, Inc; Directly purchased stock—Merck & Co, Inc
Dr. LeRoith: Speakers bureau—Pfizer, Inc, sanofi-aventis U.S.; Consultant—Merck & Co, Inc, Novo Nordisk, Takeda Pharmaceuticals North America, Inc
Dr. Triplitt: Speakers bureau—Amylin Pharmaceuticals, Inc, Eli Lilly and Company, Novartis Pharmaceuticals, Pfizer, Inc; Consultant—Amylin Pharmaceuticals, Inc
Planning Committee Mandy Johnson, University of Kentucky College of Medicine, Jessica Brown, Kristin Dickie, Mary Johnson, Deborah Neveleff, Randy Robbin, and John Savage, NACCME-Princeton CME have disclosed that they have no relevant financial relationships with any commercial interest.
The University of Kentucky College of Medicine and NACCME-Princeton CME require faculty to inform participants whenever off-label/unapproved uses of drugs or devices are discussed in their presentations.
The following off-label/unapproved drugs are discussed: alogliptin, liraglutide, vildagliptin, and saxagliptin.
Privacy Policy
NACCME-Princeton CME protects the privacy of personal and other information regarding participants, educational partners, and joint sponsors. NACCME-Princeton CME and our joint sponsors will not release personally identifiable information to a third party without the individual's consent, except such information as is required for reporting purposes to the appropriate accrediting agency.
NACCME-Princeton CME maintains physical, electronic, and procedural safeguards that comply with federal regulations to guard your nonpublic personal information.
Copyright © 2008 by North American Center for Continuing Medical Education, LLC. All rights reserved. No part of this accredited continuing education activity may be reproduced or transmitted in any form or by any means, electronic or mechanical, without first obtaining permission from the North American Center for Continuing Medical Education.
